[go: up one dir, main page]

CY1122851T1 - Υπερλεπτο σκευασμα φορμοτερολης - Google Patents

Υπερλεπτο σκευασμα φορμοτερολης

Info

Publication number
CY1122851T1
CY1122851T1 CY20201100231T CY201100231T CY1122851T1 CY 1122851 T1 CY1122851 T1 CY 1122851T1 CY 20201100231 T CY20201100231 T CY 20201100231T CY 201100231 T CY201100231 T CY 201100231T CY 1122851 T1 CY1122851 T1 CY 1122851T1
Authority
CY
Cyprus
Prior art keywords
formulation
concentration
formoterol
inhaler
concentration comprised
Prior art date
Application number
CY20201100231T
Other languages
English (en)
Inventor
Rebecca Jaine Davies
David Ganderton
David Andrew Lewis
Brian John Meakin
Tanya Kathleen Church
Gaetano Brambilla
Alessandra Ferraris
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27790093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122851(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP02004786A external-priority patent/EP1340492A1/en
Priority claimed from EP02023589A external-priority patent/EP1415647A1/en
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of CY1122851T1 publication Critical patent/CY1122851T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

Ένα φαρμακευτικό σκεύασμα αερολύματος προς χορήγηση με έναν πεπιεσμένο δοσιμετρικό εισπνευστήρα που περιλαμβάνει ως δραστικά συστατικά φουμαρική φορμοτερόλη σε μια συγκέντρωση η οποία περιλαμβάνεται μεταξύ 0,003 και 0,192% β/ο και διπροπιονική βεκλομεθαζόνη, σε ένα διάλυμα ενός υγροποιημένου προωθητικού μέσου υδροφθοραλκανίου (ΗFΑ), αιθανόλη σε άνυδρη μορφή ως συν-διαλύτη, σε μια συγκέντρωση η οποία περιλαμβάνεται μεταξύ 10% και 20% β/β, και υδροχλωρικό οξύ, σε μια συγκέντρωση τέτοια ώστε το εύρος φαινόμενου pΗ του σκευάσματος να είναι μεταξύ 2,5 και 5,0, όπου η ποσότητα υπολειμματικού νερού είναι μικρότερη από 1500 ppm στο συνολικό βάρος του σκευάσματος, και όπου το κλάσμα σωματιδίων ίσων ή μικρότερων από 1,1 μm που παρέχεται κατά την ενεργοποίηση του εισπνευστήρα είναι τουλάχιστον 30%, για χρήση στην αντιμετώπιση μιας αναπνευστικής διαταραχής.
CY20201100231T 2002-03-01 2020-03-16 Υπερλεπτο σκευασμα φορμοτερολης CY1122851T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP02004786A EP1340492A1 (en) 2002-03-01 2002-03-01 Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP02023589A EP1415647A1 (en) 2002-10-23 2002-10-23 "Long-acting beta-2 agonists ultrafine formulations"
EP18173392.4A EP3384931B1 (en) 2002-03-01 2003-02-26 Formoterol superfine formulation
PCT/EP2003/001964 WO2003074024A1 (en) 2002-03-01 2003-02-26 Formoterol superfine formulation
EP10156461.5A EP2201964B1 (en) 2002-03-01 2003-02-26 Formoterol superfine formulation
EP03718677A EP1480615B1 (en) 2002-03-01 2003-02-26 Formoterol superfine formulation

Publications (1)

Publication Number Publication Date
CY1122851T1 true CY1122851T1 (el) 2021-05-05

Family

ID=27790093

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20101100567T CY1111133T1 (el) 2002-03-01 2010-06-18 Υπερλεπτο σκευασμα φορμοτερολης
CY20191100946T CY1122027T1 (el) 2002-03-01 2019-09-10 Υπερλεπτο σκευασμα φορμοτερολης
CY20201100230T CY1122875T1 (el) 2002-03-01 2020-03-16 Υπερλεπτο σκευασμα φορμοτερολης
CY20201100231T CY1122851T1 (el) 2002-03-01 2020-03-16 Υπερλεπτο σκευασμα φορμοτερολης

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CY20101100567T CY1111133T1 (el) 2002-03-01 2010-06-18 Υπερλεπτο σκευασμα φορμοτερολης
CY20191100946T CY1122027T1 (el) 2002-03-01 2019-09-10 Υπερλεπτο σκευασμα φορμοτερολης
CY20201100230T CY1122875T1 (el) 2002-03-01 2020-03-16 Υπερλεπτο σκευασμα φορμοτερολης

Country Status (36)

Country Link
US (4) US20050152846A1 (el)
EP (6) EP3536344B1 (el)
JP (3) JP2005523905A (el)
KR (2) KR100947409B1 (el)
CN (2) CN100398094C (el)
AR (2) AR038644A1 (el)
AT (1) ATE465712T1 (el)
AU (2) AU2003222753B2 (el)
BR (2) BRPI0308274B8 (el)
CA (2) CA2477881C (el)
CO (2) CO5611091A2 (el)
CY (4) CY1111133T1 (el)
DE (1) DE60332321D1 (el)
DK (4) DK3494995T3 (el)
EA (2) EA007735B1 (el)
ES (4) ES2342463T3 (el)
GE (2) GEP20063986B (el)
HK (1) HK1079425A1 (el)
HR (2) HRP20040752B1 (el)
HU (3) HUE048310T2 (el)
IL (3) IL163843A0 (el)
LT (3) LT3536344T (el)
MA (1) MA27175A1 (el)
ME (3) ME00077B (el)
MX (2) MXPA04008372A (el)
MY (2) MY137603A (el)
NO (2) NO20043625L (el)
NZ (2) NZ535018A (el)
PE (2) PE20030827A1 (el)
PL (2) PL209212B1 (el)
PT (4) PT3536344T (el)
RS (2) RS52387B (el)
SI (4) SI3494995T1 (el)
TN (2) TNSN04149A1 (el)
TW (2) TW200303752A (el)
WO (2) WO2003074024A1 (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
PL207377B1 (pl) * 2001-03-30 2010-12-31 Jagotec Ag Medyczny preparat aerozolowy, sposób wytwarzania medycznego preparatu aerozolowego oraz zastosowanie soli kwasów karboksylowych jako środków pomocniczych w tym preparacie
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
SI3494995T1 (sl) * 2002-03-01 2020-08-31 Chiesi Farmaceutici S.P.A. Superfina formulacija formoterola
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
CA2534120C (en) * 2003-07-31 2012-09-11 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
UA88894C2 (ru) * 2004-02-27 2009-12-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Стабильные фармацевтические композиции в виде растворов для ингаляторов с дозатором, которые находятся под давлением
IL177103A0 (en) * 2004-02-27 2006-12-10 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EA200602112A1 (ru) * 2004-05-13 2007-04-27 Кьези Фармачеутичи С. П. А. Изделие для медицинского аэрозоля
EA013428B1 (ru) * 2004-07-02 2010-04-30 Бёрингер Ингельхайм Интернациональ Гмбх РАСПЫЛЯЕМЫЕ В ВИДЕ АЭРОЗОЛЯ СУСПЕНЗИОННЫЕ КОМПОЗИЦИИ С TG 227ea ИЛИ TG 134a В КАЧЕСТВЕ ПРОПЕЛЛЕНТА
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EA013405B1 (ru) * 2005-02-25 2010-04-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Состав аэрозоля для дозирующих ингаляторов под давлением
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
GB2461752B (en) * 2008-07-14 2013-04-17 Neo Inhalation Products Ltd Metered dose inhaler
WO2010048384A2 (en) * 2008-10-23 2010-04-29 Sepracor Inc. Arformoterol and tiotropium compositions and methods for use
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
JP5914354B2 (ja) 2009-12-23 2016-05-11 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Ｃｏｐｄ用併用療法
PE20121467A1 (es) 2009-12-23 2012-11-07 Chiesi Farma Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica
EP2360147A1 (en) * 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
WO2012007729A2 (en) * 2010-07-16 2012-01-19 Cipla Limited Pharmaceutical compositions
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US20150297118A1 (en) * 2012-11-15 2015-10-22 Jp Respiratory Technology Ab Device and method for pulmonary function measurement
RU2504402C1 (ru) * 2012-11-20 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный состав в форме аэрозоля для лечения бронхиальной астмы и хронической обструктивной болезни легких
CN106667973A (zh) * 2017-01-22 2017-05-17 西咸新区世云工研坊生物科技有限公司 一种用于防雾霾损伤的组合物及其制备方法和喷剂
IL294804A (en) 2020-01-28 2022-09-01 Chiesi Farm Spa Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
GEP20247642B (en) 2020-02-20 2024-07-10 Chiesi Farm Spa Pressurised metered dose inhalers comprising buffered pharmaceutical formulation
WO2023227783A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) * 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) * 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) * 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
US4584320A (en) * 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
IT1244441B (it) * 1990-09-13 1994-07-15 Chiesi Farma Spa Dispositivo per l'inalazione boccale di farmaci aerosol
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US6299863B1 (en) * 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
US5435297A (en) * 1991-08-29 1995-07-25 Christoph Klein Medical device for inhaling metered aerosols
DE4230876A1 (de) * 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
NZ259192A (en) * 1992-12-09 1997-05-26 Boehringer Ingelheim Pharma Aerosol medicament comprising water-sensitive or solvent-sensitive active agent, hfc propellant stabilised by addition of (in)organic acid
ZA939195B (en) * 1992-12-09 1995-06-08 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
US5899201A (en) * 1993-05-26 1999-05-04 Minnesota Mining And Manufacturing Company Aerosol actuator
DE69424181T2 (de) * 1993-12-20 2000-10-19 Minnesota Mining And Mfg. Co., Saint Paul Flunisolide aerosolformulierungen
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
DE69637257T2 (de) * 1995-04-14 2008-06-12 Smithkline Beecham Corp. Verfahren zur Herstellung eines Dosierinhalators
EP1769819A3 (en) * 1995-04-14 2013-05-22 GlaxoSmithKline LLC Metered dose inhaler for fluticasone propionate
US5637505A (en) * 1995-05-19 1997-06-10 Chiron Diagnostics Corporation Method to prepare dye-based reference material
WO1998014184A1 (fr) * 1996-10-04 1998-04-09 Saitama Daiichi Seiyaku Kabushiki Kaisha Timbre percutane
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6413496B1 (en) * 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
ATE219355T1 (de) * 1997-02-05 2002-07-15 Jago Res Ag Medizinische aerosolformulierungen
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6188933B1 (en) * 1997-05-12 2001-02-13 Light & Sound Design Ltd. Electronically controlled stage lighting system
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
NZ504021A (en) * 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6045784A (en) * 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
ATE283033T1 (de) 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
PT1102579E (pt) * 1998-08-04 2003-07-31 Jago Res Ag Formulacoes de aerossol medicinais
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
ES2192866T3 (es) * 1998-11-13 2003-10-16 Jago Res Ag Polvo seco para inhalacion.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6290930B1 (en) * 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6352152B1 (en) * 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
GB2354007B (en) * 1999-09-11 2003-10-22 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6578125B2 (en) 2000-02-14 2003-06-10 Sanyo Electric Co., Ltd. Memory access circuit and memory access control circuit
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009773D0 (en) 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
EP1241113A1 (en) 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
SI3494995T1 (sl) * 2002-03-01 2020-08-31 Chiesi Farmaceutici S.P.A. Superfina formulacija formoterola
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Also Published As

Publication number Publication date
NZ535018A (en) 2007-02-23
EP3494995A3 (en) 2019-07-24
MXPA04008369A (es) 2004-11-26
IL163844A0 (en) 2005-12-18
CY1111133T1 (el) 2015-06-11
GEP20063876B (en) 2006-07-10
WO2003074024A1 (en) 2003-09-12
LT3536344T (lt) 2020-04-10
SI3536344T1 (sl) 2020-06-30
DK3494995T3 (da) 2020-03-23
TW200303767A (en) 2003-09-16
HRP20040753A2 (en) 2004-12-31
EP1480615A1 (en) 2004-12-01
SI3494995T1 (sl) 2020-08-31
AU2003222753A1 (en) 2003-09-16
EP3536344B1 (en) 2020-02-19
EP1480615B1 (en) 2010-04-28
TNSN04149A1 (en) 2007-03-12
CO5611091A2 (es) 2006-02-28
NO342575B1 (no) 2018-06-18
HRP20040752A2 (en) 2004-12-31
HUE044926T2 (hu) 2019-11-28
TNSN04147A1 (en) 2007-03-12
CY1122027T1 (el) 2020-10-14
LT3384931T (lt) 2019-09-25
WO2003074025A3 (en) 2003-12-24
AR038644A1 (es) 2005-01-19
GEP20063986B (en) 2006-12-11
TWI347197B (en) 2011-08-21
EA007735B1 (ru) 2006-12-29
MA27175A1 (fr) 2005-01-03
WO2003074025A2 (en) 2003-09-12
MY143517A (en) 2011-05-31
CN1638729A (zh) 2005-07-13
CA2477885A1 (en) 2003-09-12
KR100961603B1 (ko) 2010-06-04
KR20040093079A (ko) 2004-11-04
IL163843A (en) 2011-08-31
PL372173A1 (en) 2005-07-11
BR0308275A (pt) 2004-12-28
HUE049426T2 (hu) 2020-09-28
PT3494995T (pt) 2020-03-30
PL209212B1 (pl) 2011-08-31
DE60332321D1 (de) 2010-06-10
PT3536344T (pt) 2020-03-26
ATE465712T1 (de) 2010-05-15
BRPI0308274B8 (pt) 2021-05-25
BR0308274A (pt) 2004-12-28
PT3384931T (pt) 2019-09-26
EP3384931A1 (en) 2018-10-10
HRP20040752B1 (hr) 2012-10-31
RS76604A (en) 2006-10-27
AR038641A1 (es) 2005-01-19
ES2745064T3 (es) 2020-02-27
US20050154013A1 (en) 2005-07-14
SI1480615T1 (sl) 2010-07-30
HUE048310T2 (hu) 2020-07-28
NO20043626L (no) 2004-08-31
EP2201964A2 (en) 2010-06-30
MXPA04008372A (es) 2004-11-26
RS76704A (en) 2007-02-05
LT3494995T (lt) 2020-04-10
DK1480615T3 (da) 2010-07-12
MEP30208A (en) 2010-10-10
EP3384931B1 (en) 2019-07-24
AU2003222753B2 (en) 2008-04-17
EP1480617A2 (en) 2004-12-01
MEP30108A (en) 2010-06-10
TW200303752A (en) 2003-09-16
EA200401007A1 (ru) 2005-04-28
PE20030827A1 (es) 2003-11-06
PT1480615E (pt) 2010-06-16
EP3494995A2 (en) 2019-06-12
CA2477881C (en) 2011-02-01
CA2477881A1 (en) 2003-09-12
EP3536344A1 (en) 2019-09-11
ES2779273T3 (es) 2020-08-14
US20090263488A1 (en) 2009-10-22
US20050152846A1 (en) 2005-07-14
DK3536344T3 (da) 2020-03-16
EP2201964B1 (en) 2018-08-08
PL372292A1 (en) 2005-07-11
AU2003210370A1 (en) 2003-09-16
US8313732B2 (en) 2012-11-20
HK1079425A1 (en) 2006-04-07
JP2005523905A (ja) 2005-08-11
CO5611092A2 (es) 2006-02-28
SI3384931T1 (sl) 2019-11-29
CY1122875T1 (el) 2021-05-05
NZ535017A (en) 2007-02-23
PE20030824A1 (es) 2003-11-07
ES2780127T3 (es) 2020-08-24
EP3494995B1 (en) 2020-02-19
IL163843A0 (en) 2005-12-18
ES2342463T3 (es) 2010-07-07
DK3384931T3 (da) 2019-09-16
EA008592B1 (ru) 2007-06-29
MY137603A (en) 2009-02-27
EA200401005A1 (ru) 2005-08-25
EP2201964A3 (en) 2013-01-23
CA2477885C (en) 2010-12-21
NO20043625L (no) 2004-09-29
AU2003210370C1 (en) 2008-03-13
JP2005524664A (ja) 2005-08-18
ME00077B (me) 2010-06-10
CN1638730A (zh) 2005-07-13
CN100398094C (zh) 2008-07-02
KR20040093080A (ko) 2004-11-04
AU2003210370B2 (en) 2007-08-30
RS52387B (en) 2013-02-28
US20110061651A1 (en) 2011-03-17
KR100947409B1 (ko) 2010-03-12
BRPI0308274B1 (pt) 2018-10-30
JP2010215637A (ja) 2010-09-30

Similar Documents

Publication Publication Date Title
CY1122851T1 (el) Υπερλεπτο σκευασμα φορμοτερολης
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
MX9300620A (es) Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.
MX9207200A (es) Formulacion farmaceutica en aerosol, bote para suministrar dicha formulacion e inhalador de dosis dosificada que comprende dicho bote.
AR101593A2 (es) Formulación superfina de formoterol
IT1317846B1 (it) Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
AR002014A1 (es) Formulacion farmaceutica en aerosol, metodo para su manufactura, y metodo para la manufactura de un medicamento para el tratamiento de enfermedades atraves del tracto respiratorio que contienen a dicha formulacion.
NZ534040A (en) Metered dose inhaler
ATE418324T1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
BR9915095A (pt) Composição farmacêutica ministrável em aerosol
NO20065102L (no) Medikamenter
PE20011323A1 (es) Formulaciones farmaceuticas en solucion estable para inhaladores presurizados con medicion de dosis
AR079726A1 (es) Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
CA2474479A1 (en) Composition for inhalation
GB0323684D0 (en) Improvements in or relating to organic compounds
MX9304585A (es) Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
BR112022014228A2 (pt) Inaladores pressurizados de dose calibrada compreendendo uma formulação farmacêutica tamponada
ES2134634T3 (es) Composiciones farmaceuticas y dispositivos para su administracion.
PE20011271A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
AR040450A1 (es) Formulacion superfina de salmeterol
CO2022012207A2 (es) Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada
BR0309114A (pt) Uso de carboidratos derivados particulados em composições farmacêuticas em pó seco, composição farmacêutica em pó seco para terapia de inalação, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, e, embalagem de medicamento
MX2024006942A (es) Composicion farmaceutica que comprende salbutamol.
DE60318182D1 (de) Aerosol-formulierungen mit estern von 3,17-dihydroxyöstratrien-derivaten zur pulmonalen abgabe
WO2004103339A3 (en) Improved metered dose inhaler